SCHEMBL2915944

SCHEMBL2915944

COc1ccc(-n2nc(C(=O)N3CCN(C)CC3)cc2-c2ccccc2)nn1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 9/20 0.60
KDM4E B2RXH2 2/20 0.52
HPGD P15428 2/20 0.52
ALDH1A1 P00352 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
TACR2 P21452 1/20 0.44
TACR1 P25103 1/20 0.44
TACR3 P29371 1/20 0.44
CYP2C19 P33261 1/20 0.44
RPA1 P27694 1/20 0.44
SMPD1 P17405 1/20 0.44
PTGS2 P35354 2/20 0.43
LMNA P02545 1/20 0.43
CFTR P13569 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13637499 0.91 MALT1 (0.49) MGLLHPGDALDH1A1SMN1; SMN2NPC1
SCHEMBL2918303 0.89 MGLL (0.59) MGLLHPGDSMN1; SMN2NPC1RAB9A
SCHEMBL2921268 0.88 MGLL (0.51) MGLLKDM4EHPGDALDH1A1SMN1; SMN2
SCHEMBL5269617 0.88 MGLL (0.48) MGLLKDM4EHPGDALDH1A1SMN1; SMN2
SCHEMBL2916964 0.87 MGLL (0.46) MGLLKDM4EHPGDALDH1A1CYP1A2
SCHEMBL2919454 0.86 MGLL (0.46) MGLLKDM4EHPGDALDH1A1CYP2C9
Hydrochloric Acid SCHEMBL4247447 0.85 MGLL (0.46) MGLLKDM4EHPGDALDH1A1CYP1A2
SCHEMBL5270001 0.84 MGLL (0.44) MGLLKDM4EHPGDALDH1A1SMN1; SMN2
SCHEMBL2917284 0.84 MGLL (0.63) MGLLKDM4EHPGDALDH1A1SMN1; SMN2
SCHEMBL2919676 0.84 MGLL (0.58) MGLLKDM4EHPGDALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1591443-B1 PYRAZOLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-08-25 EP disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US disclosed
US-20060128685-A1 Pyrazole derivative DAIICHI PHARMACEUTICAL CO., LTD., (JP) 2006-06-15 US disclosed
EP-1591443-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128685-A1 Pyrazole derivative PTGS1, PTGS2, PTGER1 MGLL 2165/4885KDM4E 4322/4885HPGD 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.